litifilimab   Click here for help

GtoPdb Ligand ID: 11122

Synonyms: BIIB-059 | BIIB059
Immunopharmacology Ligand
Compound class: Antibody
Comment: Litifilimab (BIIB059) is a fully humanized IgG1, CLEC4C (blood dendritic cell antigen 2, BDCA2) targeting monoclonal antibody. It is being evaluated for ability to reduce release of disease-driving interferons (principally IFN-α) in SLE/CLE. BIIB059 was developed by Biogen, based on prior evidence of target engagement and SLE-applicable immunomodulatory efficacy of a humanized mAb against BDCA2 named 24F4A [3].
Immunopharmacology Comments
BIIB059 is an investigational mAb targeting BDCA2, that is designed to disrupt type I IFN production by pDCs, as a disease-modifying mechanism to treat SLE.
Immunopharmacology Disease
Disease X-Refs Comment References
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
Clinical lead for SLE and CLE.